 "Dr Reddy's Q1 net down 76% at Rs 154 cr")
Dr Reddy's Laboratories Limited announced today that it has launched Aripiprazole tablets in 2 mg, 5 mg, 10 mg, and 30 mg, a therapeutic equivalent generic version of Ablify tablets in the US market following the approval from the US Food and Drug Administration (USFDA).
This anti-psychotic drug is mainly used to treat patients with schizophrenia and bipolar disorder.
This is a significant launch for Dr Reddy's as the Abilify brand and generic tablets had US sales of approximately $3.1 billion for the most recent twelve months ending in August 2016, according to IMS Health data.
Abilify is a registered trademark of Otsuka Pharmaceutical Company, Japan.
